“Launching this new manufacturing site marks an important milestone for Pacira and advances our commitment to providing an opioid alternative to as many surgical patients as possible,” said Dave Stack, chairman and chief executive officer, Pacira. “Thermo Fisher Scientific is a global leader in pharmaceutical manufacturing and we look forward to advancing this partnership to meet the growing demand for Exparel as the only opioid-free, long-acting, local and regional analgesic approved for infiltration, field blocks and interscalene brachial plexus nerve block.”
